23:51 , Mar 14, 2019 |  BC Week In Review  |  Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
18:16 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting ROR1 or the long non-coding RNA (lncRNA) MAYA could help treat bone-metastatic breast cancer. In a bone-metastatic human breast cancer line, ROR1 knockout or MAYA...
07:00 , Oct 24, 2016 |  BioCentury  |  Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

Oncternal, Tokalas deal

Cancer companies Oncternal and Tokalas merged and will retain the Oncternal name. Oncternal’s cirmtuzumab (UC-961), a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in Phase I testing to treat relapsed...